MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-12-2025
Interpace Biosciences Total Liabilities 2011-2026 | IDXG
Annual Total Liabilities Interpace Biosciences
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17 M | 22.1 M | 32.5 M | 34.3 M | 28.2 M | 56 M | 15.5 M | 13.7 M | 35.2 M | 54.7 M | 95.8 M | 36.6 M | 42.8 M | 53.9 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 95.8 M | 13.7 M | 38.5 M |
Quarterly Total Liabilities Interpace Biosciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 12.3 M | 13.5 M | 15.1 M | 17 M | 25.2 M | 25.5 M | 26.7 M | 28.2 M | 30.4 M | 31.6 M | 31.9 M | 32.5 M | 30.4 M | 36.9 M | 36.2 M | 34.3 M | 32.4 M | 32.4 M | 30.2 M | 28.2 M | 28.2 M | 28.2 M | 28.2 M | 29.8 M | 29.8 M | 29.8 M | 29.8 M | 15.7 M | 15.5 M | 15.5 M | 15.5 M | 13.7 M | 13.7 M | 13.7 M | 13.7 M | 35.2 M | 35.2 M | 35.2 M | 35.2 M | 54.7 M | 54.7 M | 54.7 M | 54.7 M | 95.8 M | 95.8 M | 95.8 M | 95.8 M | 36.6 M | 36.6 M | 36.6 M | 36.6 M | 42.8 M | 42.8 M | 42.8 M | 42.8 M | 53.9 M | 53.9 M | 53.9 M | 53.9 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 95.8 M | 12.3 M | 36.4 M |
Total Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
1.62 B | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
58.6 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
87.3 M | - | -61.36 % | $ 2.46 M |  USA |
 |
Brainsway Ltd.
BWAY
|
14.4 M | $ 19.0 | 0.11 % | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
433 M | $ 20.8 | 0.85 % | $ 226 M |  China |
 |
Biocept
BIOC
|
22 M | - | -13.05 % | $ 7.29 M | USA |
 |
Chembio Diagnostics
CEMI
|
44.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Co-Diagnostics
CODX
|
9.31 M | $ 0.17 | -5.26 % | $ 4.99 M | USA |
 |
BioNano Genomics
BNGO
|
41.3 M | $ 1.52 | 1.2 % | $ 1.93 M | USA |
 |
Castle Biosciences
CSTL
|
75.4 M | $ 39.06 | -0.64 % | $ 1.08 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
21.6 M | - | - | $ 562 M |  Britain |
 |
Danaher Corporation
DHR
|
31.8 B | $ 229.23 | -0.65 % | $ 168 B | USA |
 |
DermTech
DMTK
|
64.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
7.26 M | $ 10.98 | 2.62 % | $ 312 M | Israel |
 |
DexCom
DXCM
|
4.2 B | $ 66.52 | -0.81 % | $ 25.7 B | USA |
 |
Enzo Biochem
ENZ
|
29.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
3.53 B | $ 101.86 | -0.04 % | $ 18.9 B | USA |
 |
Fulgent Genetics
FLGT
|
90.8 M | $ 26.19 | -1.13 % | $ 792 M | USA |
 |
Global Cord Blood Corporation
CO
|
3.65 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
186 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
4.37 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
427 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
2.7 B | - | - | $ 10.7 B | USA |
 |
CareDx, Inc
CDNA
|
205 M | $ 18.93 | -0.73 % | $ 1.02 B | USA |
 |
Celcuity
CELC
|
130 M | $ 99.58 | -0.34 % | $ 3.93 B | USA |
 |
Anixa Biosciences
ANIX
|
2.7 M | $ 3.13 | 0.32 % | $ 99.8 K | USA |
 |
Heska Corporation
HSKA
|
164 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
12.4 M | - | -20.0 % | $ 1.06 M | USA |
 |
Guardant Health
GH
|
1.63 B | $ 102.21 | 1.6 % | $ 12.5 B | USA |
 |
Aspira Women's Health
AWH
|
10.6 M | - | -6.19 % | $ 10.5 M | USA |
 |
IQVIA Holdings
IQV
|
20.8 B | $ 225.57 | -0.92 % | $ 40.9 B | USA |
 |
ENDRA Life Sciences
NDRA
|
1.89 M | $ 4.45 | -6.62 % | $ 2.39 M | USA |
 |
Illumina
ILMN
|
2.7 B | $ 130.74 | -1.51 % | $ 20.8 B | USA |
 |
Charles River Laboratories International
CRL
|
4.02 B | $ 200.01 | -0.93 % | $ 10.3 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
16.9 B | $ 27.17 | -0.79 % | $ 20 B |  Niderland |
 |
Quidel Corporation
QDEL
|
538 M | $ 28.49 | -2.76 % | $ 1.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
7.16 B | $ 173.69 | -1.03 % | $ 19.3 B | USA |
|
Biodesix
BDSX
|
76.4 M | $ 6.75 | 0.45 % | $ 875 M | USA |
 |
Motus GI Holdings
MOTS
|
4.54 M | - | -34.28 % | $ 263 K | Israel |
 |
Laboratory Corporation of America Holdings
LH
|
10.3 B | $ 251.26 | -0.72 % | $ 21.1 B | USA |
 |
ICON Public Limited Company
ICLR
|
7.35 B | $ 181.71 | -0.7 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
1.7 B | $ 676.07 | -0.92 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
892 M | $ 66.81 | -0.52 % | $ 4.62 B | USA |
 |
Mettler-Toledo International
MTD
|
3.37 B | $ 1 396.59 | -1.25 % | $ 29.6 B |  Schweiz |
 |
Agilent Technologies
A
|
5.32 B | $ 136.49 | -0.81 % | $ 41.5 B | USA |
 |
Myriad Genetics
MYGN
|
326 M | $ 6.12 | -0.89 % | $ 554 M | USA |
 |
Biomerica
BMRA
|
1.84 M | $ 2.5 | 2.04 % | $ 5.74 M | USA |
 |
Bioventus
BVS
|
590 M | $ 7.44 | -0.13 % | $ 466 M | USA |
 |
QIAGEN N.V.
QGEN
|
3.11 B | $ 45.03 | -0.64 % | $ 10 B | Niderland |
 |
NeoGenomics
NEO
|
736 M | $ 11.82 | -3.35 % | $ 1.5 B | USA |